Niels-Henrik von Holstein-Rathlou, who has led the Novo Nordisk Foundation’s activities within biomedical and health science for the past 7 years, has decided to step down so he can spend more time on projects outside the Foundation.
As a result, the Foundation has decided to merge Biomedicine & Health Sciences and Clinical Science into one larger Medical Science department. Martin Ridderstråle, who previously led Clinical Science as Senior Vice President, has been appointed as head of the new department.
“I would like to thank Niels-Henrik for his fantastic contribution. He has been responsible for the Foundation’s largest grant area and has led many of the Foundation’s most important initiatives within biomedicine during a period when the Foundation has increased its grants substantially,” says Mads Krogsgaard Thomsen, CEO of the Novo Nordisk Foundation.
“Niels-Henrik has decided that the end of the Foundation’s current strategy period and the development of the Foundation’s new long-term 2030 strategy is an opportune time for him to step down,” adds Mads Krogsgaard Thomsen.
Martin Ridderstråle is a former Adjunct Professor of Endocrinology at Lund University, Sweden and served as Head of Clinic for 3 years at Steno Diabetes Center in Gentofte, Denmark. Before joining the Foundation in 2020, he served as Corporate Vice President at Novo Nordisk A/S, where he was head of Clinical Pharmacology and Translational Medicine. He previously held several managerial positions within endocrinology and diabetology at Skåne University Hospital in Sweden.
Further information
Christian Mostrup, Senior Programme Lead, Communications, +45 3067 4805, [email protected]
